Ilaria De Pascale

Dr. Ilaria De Pascale

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MGMarco Gioia
Marco Gioia
MBMaddalena DE BERNARDO
Maddalena DE BERNARDO
SPSergio Pagliarulo
Sergio Pagliarulo
Ferdinando CioneFerdinando Cione
Ferdinando Cione
FMFrancesco Ferdinando Mottola
Francesco Ferdinando Mottola
Nicola RosaNicola Rosa
Nicola Rosa
The purpose of this study is to evaluate choroidal thickness (ChT) at the subfoveal and peripheral level after the instillation of 0.5% tropicamide + 10% phenylephrine 9 hydrochloride eye drops by using OCT scans in enhanced depth image (EDI) mode. In total, 53 patients (30 males and 23 females) were involved, and the mean age was 25.62 ± 2.41 (age range: 23–36). The dominant eye was treated with tropicamide + phenylephrine (Visumidriatic Fenil 100 mg/mL + 5 mg/mL, Visufarma) while the nondominant eye was used as the control. An OCT analysis was performed on both eyes before and 30 min after the instillation of a drop of mydriatic in the dominant eye. The ChT was measured by using the OCT software measurement tool (Spectralis; Heidelberg Engineering; Heidelberg, Germany, version 6.0). The results showed a statistically significant ChT decrease (p = 0.009) in the temporal sector after the treatment with tropicamide + phenylephrine. In the subfoveal and nasal sectors, no statistically significant ChT changes were detected (p = 0.94; p = 0.85) following the administration of the mydriatic eye drops. The ChT thinning in the temporal sector following the instillation of the tropicamide + phenylephrine eye drops suggests that in the case of ChT studies, mydriatic administration should be avoided.

3 June 2024 in Life
Verified
Journal Article
Open access
PDF file
Livio VitielloLivio Vitiello
Livio Vitiello
GSGiulio Salerno
Giulio Salerno
ACAlessia Coppola
Alessia Coppola
IPIlaria De Pascale
Ilaria De Pascale
GAGiulia Abbinante
Giulia Abbinante
Giuseppe GiannaccareGiuseppe Giannaccare
Giuseppe Giannaccare
Among working-age people, diabetic retinopathy and diabetic macular edema are currently considered the main causes of blindness. Nowadays, intravitreal injections are widely acknowledged as a significant milestone in ophthalmology, especially for the treatment of several retinal diseases, including diabetic macular edema. In particular, anti-vascular endothelial growth factor (VEGF) agents are typically the first line of treatment; however, monthly injections are required, at least, during the loading dosage. Notably, an intravitreal 0.7 mg dexamethasone (DEX) implant (Ozurdex®, AbbVie Inc., North Chicago, IL, USA) is considered a legitimate substitute treatment for diabetic eyes that have not responded to anti-VEGF treatment. In fact, clinical trials and real-life studies have demonstrated the effectiveness and safety of an intravitreal DEX implant in treating such conditions over a period of three to six months. For this reason, wisely selecting diabetic patients might be crucial to decreasing the load of injections in clinics and hospitals. The purpose of this review is to analyze the available scientific literature to highlight the benefits, efficacy, and clinical criteria for choosing whether to switch from intravitreal anti-VEGF therapy to an intravitreal DEX implant in diabetic macular edema.

23 August 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Livio VitielloLivio Vitiello
Livio Vitiello
FLFilippo Lixi
Filippo Lixi
ACAlessia Coppola
Alessia Coppola
GAGiulia Abbinante
Giulia Abbinante
VGVincenzo Gagliardi
Vincenzo Gagliardi
Giuseppe GiannaccareGiuseppe Giannaccare
Giuseppe Giannaccare
Nowadays, retinal vein occlusion (RVO) is the second most prevalent cause of vision loss associated with retinal vascular disease. Intravitreal injections are currently known as a major advancement in ophthalmology, particularly in the treatment of RVO and other retinal disorders. Particularly, the first line of therapy is usually anti-vascular endothelial growth factor (VEGF) drugs. Notably, for RVO eyes that have not responded to anti-VEGF therapy, an intravitreal dexamethasone (DEX) implant 0.7 mg (Ozurdex®, AbbVie Inc., North Chicago, IL, USA) is considered a suitable therapeutical substitute. Actually, investigations carried out in the real world and clinical trials have shown the safety and the efficacy of intravitreal DEX implants for treating this retinal disease. For this reason, choosing patients carefully may thus be essential to reduce the number of injections that clinics and hospitals have to do to manage RVO and its complications. The primary aim of this review is to summarize the pathophysiology of this retinal vascular disease, as well as the clinical and ocular imaging features that may support a switch from prior anti-VEGF treatment to intravitreal DEX implant, to provide the RVO patients with the best possible treatment to ensure maximum visual recovery.

Verified
Journal Article
Open access
PDF file
MBMaddalena DE BERNARDO
Maddalena DE BERNARDO
Ferdinando CioneFerdinando Cione
Ferdinando Cione
IPIlaria De Pascale
Ilaria De Pascale
SPSergio Pagliarulo
Sergio Pagliarulo
Nicola RosaNicola Rosa
Nicola Rosa
In this study, intraocular pressure (IOP) was measured in sitting, supine, prone, and standing (ST) positions and again five minutes after standing (ST-5) utilizing a Tono-Pen AVIA in 124 eyes of 62 healthy subjects with ages ranging from 21 to 59 years (mean 30 ± 10 years). In each subject, the average IOP of both eyes was used for the statistical evaluation. The mean IOP difference between the ST and sitting positions was −0.13 ± 1.63 mmHg (p = 0.548); between ST-5 and sitting, it was 0.53 ± 1.24 mmHg (p = 0.001); between supine and sitting, it was 1.30 ± 1.48 mmHg (p < 0.001); between ST and supine, it was −1.43 ± 1.74 mmHg (p < 0.001); between ST-5 and supine, it was −0.77 ± 1.59 mmHg (p < 0.001); between prone and supine, it was 2.24 ± 1.92 mmHg (p < 0.001); between ST and ST-5, it was −0.67 ± 1.84 mmHg (range: −7.5 to 5 mmHg) (p = 0.007); between prone and ST, it was 3.46 ± 2.01 mmHg (p < 0.001); between ST-5 and prone, it was −2.46 ± 1.67 mmHg (p < 0.001); and between sitting and prone, it was −3.22 ± 1.56 mmHg (p < 0.001). The results show a significant IOP increase in the ST-5 position, suggesting that such measurements need to be performed in an attempt to explain the progression of glaucoma in apparently normal-tension patients.

8 September 2025 in Life
Verified
Journal Article
Open access
PDF file
Livio VitielloLivio Vitiello
Livio Vitiello
FLFilippo Lixi
Filippo Lixi
VCValerio Calabresi
Valerio Calabresi
MTMario Troisi
Mario Troisi
IPIlaria De Pascale
Ilaria De Pascale
Giuseppe GiannaccareGiuseppe Giannaccare
Giuseppe Giannaccare
The number of people affected by myopia worldwide is estimated to reach two billion and to further grow. Therefore, numerous treatment approaches (pharmacological, behavioral, environmental, and optical) have been put forth to slow the progression of myopia, especially in children. Among these, spectacle lenses represent a straightforward and less intrusive therapeutic approach for children and their parents. For this reason, in recent years, several spectacle lenses with different technologies have been developed to slow myopia progression and enhance the quality of life for myopic children, thus trying to reduce the related health care burden. According to the published scientific literature, three different types of spectacle lenses are currently the most validated optical options for myopia management: (i) Defocus Incorporated Multiple Segments lenses (DIMS), (ii) Highly Aspherical Lenslet Target lenses (HALT) and (iii) Cylindrical Annular Refractive Elements (CARE) lenses. The aim of this narrative review is to exclusively discuss the scientific evidence of these three different spectacles lenses, and to point out the potential benefits and drawbacks in their use for myopia control and management.

30 December 2024 in Life
Verified
Journal Article
Open access
PDF file
Livio VitielloLivio Vitiello
Livio Vitiello
MBMaddalena DE BERNARDO
Maddalena DE BERNARDO
IPIlaria De Pascale
Ilaria De Pascale
GSGiulio Salerno
Giulio Salerno
APAlfonso Pellegrino
Alfonso Pellegrino
Nicola RosaNicola Rosa
Nicola Rosa
The abnormal growth of irregular new blood vessels into the subretinal or intraretinal space is known as macular neovascularization (MNV). People over 50 are often affected by this disorder, which is typically brought on by age-related macular degeneration. In addition, MNV can be found in people under 50 years of age, who may present primary ophthalmic diseases such as pathological myopia, angioid streaks, traumatic choroidal rupture, or suspected ocular histoplasmosis syndrome. However, it is important to consider a specific set of young individuals who may develop MNV even in the absence of pathological myopia or other identifiable inflammatory, peripapillary, post-traumatic, or degenerative fundus abnormalities. This latter condition is classified as idiopathic MNV. After a literature review focused on young patients affected by one of these two clinical entities, we report the case of a Caucasian young woman suffering for four years from an idiopathic and quiescent MNV that started exuding after childbirth, probably due to the induction with oxytocin, and was treated with intravitreal Aflibercept 2 mg injections.